Acetylcholine receptor alpha subunit (nAChR α subunit)

The acetylcholine receptor alpha subunit is a key component of nicotinic acetylcholine receptors, which are pentameric ligand-gated ion channels found in the neuromuscular junction, brain, and peripheral ganglia. There are multiple isoforms (e.g., α1 in muscle, α2–α10 in neurons) that combine with other subunits to assemble functional receptor complexes. The alpha subunit contains the primary ligand (acetylcholine) binding sites and is essential for channel gating and pharmacological specificity. Upon acetylcholine binding to the alpha subunits, conformational changes occur, opening the central ion channel and allowing cation flow, resulting in depolarization and triggering downstream physiological responses such as skeletal muscle contraction or neuronal signaling. Mutations or autoantibody targeting of the alpha subunit can lead to human diseases, including myasthenia gravis and some congenital neuromuscular syndromes. The receptor is an established therapeutic target in anesthesia, neuropsychiatric conditions, and as an immunological marker. If you need information for a specific human alpha subunit (e.g., muscle α1, neuronal α4, α7), this framework can be refined accordingly.

Other names

Nicotinic acetylcholine receptor alpha subunitnAChR alpha subunitMuscle-type acetylcholine receptor alpha subunit (for α1)Neuronal acetylcholine receptor alpha subunit (e.g., α2–α10)Alpha 1 subunit of nicotinic acetylcholine receptor (nAChR α1)CHRNA (gene family designation, e.g., CHRNA1, CHRNA4, CHRNA7)AChR α-subunit

Agonist binding opens ligand-gated ion channel, permitting cation influx (Na⁺, K⁺, Ca²⁺) and depolarization; Competitive antagonists/blockers prevent channel opening, inhibiting neurotransmission; Partial agonists modulate receptor activity without maximal effect (varenicline); Desensitization with sustained agonist exposure; Allosteric modulation (e.g., galantamine at nAChRs)